KCND3 as a Radioligand Therapy Target
KCND3, potassium voltage-gated channel subfamily D member 3, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, KCND3 staining is highest in breast cancer (92% of samples positive), thyroid cancer (75% of samples positive) and neuroendocrine tumors (75% of samples positive). Clinical status: Clinical-stage (up to phase 2, any modality).
Is KCND3 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in breast cancer, 92% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: Clinical-stage (up to phase 2, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
KCND3 expression in cancer
Protein expression of KCND3 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Breast Cancer | 0.56 | High | 92% |
| Thyroid Cancer | 0.50 | Medium | 75% |
| Neuroendocrine Tumors | 0.50 | Medium | 75% |
| Ovarian Cancer | 0.42 | Medium | 75% |
| Cervical Cancer | 0.42 | Medium | 75% |
| Bladder Cancer | 0.39 | Medium | 73% |
| Skin Cancer | 0.39 | Medium | 67% |
| Endometrial Cancer | 0.30 | Medium | 64% |
| Colorectal Cancer | 0.21 | Medium | 46% |
| Lung Cancer | 0.20 | Medium | 50% |
| Glioma | 0.19 | Low | 50% |
| Liver Cancer | 0.19 | Low | 33% |
| Pancreatic Cancer | 0.18 | Low | 46% |
| Head and Neck Cancer | 0.17 | Low | 25% |
| Melanoma | 0.15 | Low | 27% |
| Lymphoma | 0.11 | Low | 25% |
| Prostate Cancer | 0.06 | Low | 18% |
| Gastric Cancer | 0.06 | Low | 9% |
| Kidney Cancer | 0.03 | Low | 8% |
| Testicular Cancer | 0.03 | Low | 8% |
Is KCND3 internalized?
Nuclens has not yet extracted internalization evidence for KCND3. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
KCND3 clinical trials
Clinical-stage (up to phase 2, any modality). Nuclens hasn't indexed trials for KCND3 yet. Search ClinicalTrials.gov for KCND3 trials.
KCND3 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See KCND3 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
KCND3 gene essentiality (DepMap)
CRISPR knockout effect across 1254 cancer cell lines: -0.19 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related breast cancer radioligand targets
HER3 (ERBB3) · c-MET (MET) · FAP · HER2 (ERBB2) · STEAP2 · EGFR · B7-H3 (CD276) · SSTR2
See all radioligand therapy targets in breast cancer.
See how KCND3 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.